{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T09:18:46Z","timestamp":1794907126856,"version":"4.9.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["303531\/2020-7"],"award-info":[{"award-number":["303531\/2020-7"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.phrs.2022.106075","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T11:56:16Z","timestamp":1641815776000},"page":"106075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Evaluation of the analgesic effect of \u0251-lipoic acid in treating pain disorders: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"177","author":[{"given":"Gabriela","family":"Cassanego","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliane","family":"De Freitas Bauermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Trevisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2022.106075_bib1","series-title":"Serotonin Syst","first-page":"203","article-title":"Chapter twelve - serotonin and nociception: from nociceptive transduction at the periphery to pain modulation from the brain","author":"Martins","year":"2019"},{"key":"10.1016\/j.phrs.2022.106075_bib2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.nrl.0000263703.78318.2b","article-title":"Alpha-lipoic acid may improve symptomatic diabetic polyneuropathy","volume":"13","author":"Tang","year":"2007","journal-title":"Neurologist"},{"key":"10.1016\/j.phrs.2022.106075_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/676725","article-title":"Chronic pain: new insights in molecular and cellular mechanisms","volume":"2015","author":"Luongo","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.phrs.2022.106075_bib4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.biopha.2006.06.011","article-title":"Modern concepts of acute and chronic pain management","volume":"60","author":"Spacek","year":"2006","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2022.106075_bib5","series-title":"Handb. Sleep Disord. Med. Cond.","first-page":"201","article-title":"Chapter 9 - chronic pain","author":"Murray","year":"2019"},{"key":"10.1016\/j.phrs.2022.106075_bib6","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.sjpain.2016.05.039","article-title":"A randomized controlled trial of amitriptyline versus gabapentin for complex regional pain syndrome type I and neuropathic pain in children.","volume":"13","author":"Brown","year":"2016","journal-title":"Scand. J. Pain."},{"key":"10.1016\/j.phrs.2022.106075_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/j.pain.0000000000001365","article-title":"The IASP classification of chronic pain for ICD-11: chronic neuropathic pain","volume":"160","author":"Scholz","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.phrs.2022.106075_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-019-0092-1","article-title":"Diabetic neuropathy","volume":"5","author":"Feldman","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.phrs.2022.106075_bib9","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.2337\/dc11-0503","article-title":"Efficacy and safety of antioxidant treatment with \u03b1-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial","volume":"34","author":"Ziegler","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2022.106075_bib10","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1177\/0300060518756540","article-title":"Effect of \u03b1-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy","volume":"46","author":"Agathos","year":"2018","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.phrs.2022.106075_bib11","doi-asserted-by":"crossref","first-page":"770","DOI":"10.2337\/diacare.26.3.770","article-title":"The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the Sydney trial","volume":"26","author":"Ametov","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2022.106075_bib12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ejpain.2008.06.004","article-title":"Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: a double-blind, randomized, placebo-controlled study","volume":"13","author":"Carbone","year":"2009","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.phrs.2022.106075_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119469","article-title":"Role of TRPA1 expressed in bone tissue and the antinociceptive effect of the TRPA1 antagonist repeated administration in a breast cancer pain model","volume":"276","author":"de Almeida","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2022.106075_bib14","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/ijc.32648","article-title":"Dacarbazine alone or associated with melanoma-bearing cancer pain model induces painful hypersensitivity by TRPA1 activation in mice","volume":"146","author":"Brusco","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2022.106075_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ph14080831","article-title":"Periorbital nociception in a progressive multiple sclerosis mouse model is dependent on TRPA1 channel activation","volume":"14","author":"Dalenogare","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.phrs.2022.106075_bib16","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/cns.13303","article-title":"Alpha-lipoic acid downregulates TRPV1 receptor via NF-\u03baB and attenuates neuropathic pain in rats with diabetes","volume":"26","author":"Zhang","year":"2020","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.phrs.2022.106075_bib17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/j.pain.0000000000002028","article-title":"Double-blind, randomized, placebo-controlled crossover trial of alpha-lipoic acid for the treatment of fibromyalgia pain: the IMPALA trial","volume":"162","author":"Gilron","year":"2021","journal-title":"Pain"},{"key":"10.1016\/j.phrs.2022.106075_bib18","first-page":"1223","article-title":"Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial","volume":"22","author":"Guo","year":"2014","journal-title":"Support Care Cancer J. Multinatl. Assoc. Support Cancer Care"},{"key":"10.1016\/j.phrs.2022.106075_bib19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2842.2008.01914.x","article-title":"Efficacy of alpha lipoic acid in burning mouth syndrome: a randomized, placebo-treatment study","volume":"36","author":"L\u00f3pez-Jornet","year":"2009","journal-title":"J. Oral Rehabil."},{"key":"10.1016\/j.phrs.2022.106075_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1526-4610.2006.00626.x","article-title":"A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis","volume":"47","author":"Magis","year":"2007","journal-title":"Headache"},{"key":"10.1016\/j.phrs.2022.106075_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5704\/MOJ.2003.001","article-title":"The use of alfa-lipoic acid-R (ALA-R) in patients with mild-moderate carpal tunnel syndrome: a randomised controlled open label prospective study","volume":"14","author":"Passiatore","year":"2020","journal-title":"Malays. Orthop. J."},{"key":"10.1016\/j.phrs.2022.106075_bib22","first-page":"158","article-title":"Alpha lipoic acid: a new treatment for neuropathic pain in patients with diabetes?","volume":"68","author":"Mijnhout","year":"2010","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.phrs.2022.106075_bib23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1464-5491.2004.01109.x","article-title":"Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis","volume":"21","author":"Ziegler","year":"2004","journal-title":"Diabet. Med."},{"key":"10.1016\/j.phrs.2022.106075_bib24","unstructured":"M. Offringa, M. Farid-Kapadia, L. Askie, L.Hartling, D. Contopoulos- Ioannidis, Z.A. Bhutta, R. Soll, D. Moher, Preferred reporting items for systematic review and meta-analysis protocols and reports -extension for children: PRISMA-PC and PRISMA-C 2020, in: Advances in Evidence Synthesis: Special Issue Cochrane Database of Systematic Reviews (2020) (9 Supl 1)."},{"key":"10.1016\/j.phrs.2022.106075_bib25","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2022.106075_bib26","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.phrs.2022.106075_bib27","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2022.106075_bib28","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1007\/s12035-021-02493-9","article-title":"Advanced oxidative protein products role in multiple sclerosis: a systematic review and meta-analysis","volume":"58","author":"Rodrigues","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.phrs.2022.106075_bib29","first-page":"445","article-title":"Systematic assessment and characterization of chronic pain in multiple sclerosis patients","volume":"39","author":"Ferraro","year":"2018","journal-title":"Neurol. Sci. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol."},{"key":"10.1016\/j.phrs.2022.106075_bib30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.phrs.2022.106075_bib31","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.4317\/medoral.20410","article-title":"Alpha lipoic acid efficacy in burning mouth syndrome. A controlled clinical trial","volume":"20","author":"Palacios-S\u00e1nchez","year":"2015","journal-title":"Med. Oral. Patol. Oral. Cir. Bucal"},{"key":"10.1016\/j.phrs.2022.106075_bib32","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/189857","article-title":"Treatment with \u03b1-lipoic acid over 16 weeks in type 2 diabetic patients with symptomatic polyneuropathy who responded to initial 4-week high-dose loading","volume":"2015","author":"Garcia-Alcala","year":"2015","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.phrs.2022.106075_bib33","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/10715769900300721","article-title":"Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha lipoic acid in diabetic neuropathy","volume":"31","author":"Reljanovic","year":"1999","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.phrs.2022.106075_bib34","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1046\/j.1464-5491.1999.00190.x","article-title":"Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy","volume":"16","author":"Ruhnau","year":"1999","journal-title":"Diabet. Med."},{"key":"10.1016\/j.phrs.2022.106075_bib35","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/BF00400603","article-title":"Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study)","volume":"38","author":"Ziegler","year":"1995","journal-title":"Diabetologia"},{"key":"10.1016\/j.phrs.2022.106075_bib36","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.2337\/diacare.22.8.1296","article-title":"Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy","volume":"22","author":"Ziegler","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2022.106075_bib37","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2337\/dc06-1216","article-title":"Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial","volume":"29","author":"Ziegler","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2022.106075_bib38","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jdiacomp.2015.10.018","article-title":"Predictors of improvement and progression of diabetic polyneuropathy following treatment with \u03b1-lipoic acid for 4 years in the NATHAN 1 trial","volume":"30","author":"Ziegler","year":"2016","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.phrs.2022.106075_bib39","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2022.106075_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/j.pain.0000000000001384","article-title":"Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11)","volume":"160","author":"Treede","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.phrs.2022.106075_bib41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/papr.12054","article-title":"Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy","volume":"14","author":"Snedecor","year":"2014","journal-title":"Pain. Pract."},{"key":"10.1016\/j.phrs.2022.106075_bib42","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/biom9080356","article-title":"Insights on the use of \u03b1-lipoic acid for therapeutic purposes","volume":"9","author":"Salehi","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.phrs.2022.106075_bib43","series-title":"A Rev. Biomater. Their Appl. Drug Deliv.","first-page":"9","article-title":"Classification of drug delivery systems","author":"Reza Rezaie","year":"2018"},{"key":"10.1016\/j.phrs.2022.106075_bib44","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2022.106075_bib45","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1177\/0022034518782462","article-title":"Recent advances in the etiology and treatment of burning mouth syndrome","volume":"97","author":"Ritchie","year":"2018","journal-title":"J. Dent. Res."},{"key":"10.1016\/j.phrs.2022.106075_bib46","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/jphp.13241","article-title":"Treatment of diabetic peripheral neuropathy: a review","volume":"72","author":"Khdour","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.phrs.2022.106075_bib47","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ejphar.2018.06.034","article-title":"Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets","volume":"833","author":"Dewanjee","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2022.106075_bib48","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1111\/dme.13083","article-title":"Systematic review of treatments for diabetic peripheral neuropathy","volume":"33","author":"\u00c7akici","year":"2016","journal-title":"Diabet. Med."},{"key":"10.1016\/j.phrs.2022.106075_bib49","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40122-017-0085-2","article-title":"A review of neuropathic pain: from diagnostic tests to mechanisms","volume":"6","author":"Truini","year":"2017","journal-title":"Pain. Ther."},{"key":"10.1016\/j.phrs.2022.106075_bib50","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3390\/antiox9101011","article-title":"Safety evaluation of \u03b1-lipoic acid supplementation: a systematic review and meta-analysis of randomized placebo-controlled clinical studies","volume":"9","author":"Fogacci","year":"2020","journal-title":"Antioxidants"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822000202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822000202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:28:43Z","timestamp":1760912923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822000202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":50,"alternative-id":["S1043661822000202"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106075","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the analgesic effect of \u0251-lipoic acid in treating pain disorders: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106075"}}